KYMERA THERAPEUTICS, INC. Other Nonoperating Income
KYMERA THERAPEUTICS, INC. (KYMR) reported Other Nonoperating Income of $14.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncome · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. other nonoperating income for the quarter ending 2026-06-30 was $14.48M, a 79.82% increase year-over-year.
- KYMERA THERAPEUTICS, INC. other nonoperating income for the quarter ending 2026-03-31 was $14.98M, a 68.00% increase year-over-year.
- KYMERA THERAPEUTICS, INC. other nonoperating income for the quarter ending 2025-12-31 was $11.01M, a 9.37% increase year-over-year.
- KYMERA THERAPEUTICS, INC. other nonoperating income for the quarter ending 2025-09-30 was $10.44M, a 7.70% increase year-over-year.
- KYMERA THERAPEUTICS, INC. other nonoperating income for fiscal 2025 was $38.42M, a 1.03% increase from fiscal 2024.
- KYMERA THERAPEUTICS, INC. other nonoperating income for fiscal 2024 was $38.03M, a 102.65% increase from fiscal 2023.
- KYMERA THERAPEUTICS, INC. other nonoperating income for fiscal 2023 was $18.76M, a 183.27% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. other nonoperating income for fiscal 2022 was $6.62M, a 1257.38% increase from fiscal 2021.
| Period end | Other Nonoperating Income 3 month | Other Nonoperating Income 6 month | Other Nonoperating Income 9 month | Other Nonoperating Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.48M 10-Q · filed 2026-08-05 | $29.46M 10-Q · filed 2026-08-05 | $40.46M derived: sum of 3 quarters · filed 2026-08-05 | $50.91M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $14.98M 10-Q · filed 2026-04-30 | $25.99M derived: sum of 2 quarters · filed 2026-04-30 | $36.43M derived: sum of 3 quarters · filed 2026-04-30 | $44.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $11.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $21.45M derived: sum of 2 quarters · filed 2026-02-26 | $29.50M derived: sum of 3 quarters · filed 2026-08-05 | $38.42M 10-K · filed 2026-02-26 |
| 2025-09-30 | $10.44M 10-Q · filed 2025-11-04 | $18.50M derived: sum of 2 quarters · filed 2026-08-05 | $27.41M 10-Q · filed 2025-11-04 | $37.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $8.05M 10-Q · filed 2026-08-05 | $16.97M 10-Q · filed 2026-08-05 | $27.03M derived: sum of 3 quarters · filed 2026-08-05 | $36.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $8.92M 10-Q · filed 2026-04-30 | $18.98M derived: sum of 2 quarters · filed 2026-04-30 | $28.68M derived: sum of 3 quarters · filed 2026-04-30 | $37.60M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $10.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $19.76M derived: sum of 2 quarters · filed 2026-02-26 | $28.68M derived: sum of 3 quarters · filed 2026-02-26 | $38.03M 10-K · filed 2026-02-26 |
| 2024-09-30 | $9.70M 10-Q · filed 2025-11-04 | $18.62M derived: sum of 2 quarters · filed 2025-11-04 | $27.96M 10-Q · filed 2025-11-04 | $32.96M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $8.92M 10-Q · filed 2025-08-11 | $18.27M 10-Q · filed 2025-08-11 | $23.26M derived: sum of 3 quarters · filed 2026-02-26 | $27.95M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $9.34M 10-Q · filed 2025-05-09 | $14.34M derived: sum of 2 quarters · filed 2026-02-26 | $19.02M derived: sum of 3 quarters · filed 2026-02-26 | $23.65M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.68M derived: sum of 2 quarters · filed 2026-02-26 | $14.31M derived: sum of 3 quarters · filed 2026-02-26 | $18.76M 10-K · filed 2026-02-26 |
| 2023-09-30 | $4.68M 10-Q · filed 2024-10-31 | $9.31M derived: sum of 2 quarters · filed 2024-10-31 | $13.77M 10-Q · filed 2024-10-31 | $17.59M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $4.63M 10-Q · filed 2024-08-07 | $9.09M 10-Q · filed 2024-08-07 | $12.91M derived: sum of 3 quarters · filed 2025-02-27 | $14.82M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $4.45M 10-Q · filed 2024-05-02 | $8.28M derived: sum of 2 quarters · filed 2025-02-27 | $10.19M derived: sum of 3 quarters · filed 2025-02-27 | $10.79M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $3.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $5.74M derived: sum of 2 quarters · filed 2025-02-27 | $6.33M derived: sum of 3 quarters · filed 2025-02-27 | $6.62M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.92M 10-Q · filed 2023-11-02 | $2.51M derived: sum of 2 quarters · filed 2023-11-02 | $2.80M 10-Q · filed 2023-11-02 | $2.94M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $594.00K 10-Q · filed 2023-08-03 | $884.00K 10-Q · filed 2023-08-03 | $1.03M derived: sum of 3 quarters · filed 2024-02-22 | $1.15M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $290.00K 10-Q · filed 2023-05-04 | $435.00K derived: sum of 2 quarters · filed 2024-02-22 | $560.00K derived: sum of 3 quarters · filed 2024-02-22 | $658.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $270.00K derived: sum of 2 quarters · filed 2024-02-22 | $368.00K derived: sum of 3 quarters · filed 2024-02-22 | $488.00K 10-K · filed 2024-02-22 |
| 2021-09-30 | $125.00K 10-Q · filed 2022-11-03 | $223.00K derived: sum of 2 quarters · filed 2022-11-03 | $343.00K 10-Q · filed 2022-11-03 | $465.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $98.00K 10-Q · filed 2022-08-09 | $217.00K 10-Q · filed 2022-08-09 | $340.00K derived: sum of 3 quarters · filed 2023-02-23 | $465.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $118.00K 10-Q · filed 2022-05-03 | $242.00K derived: sum of 2 quarters · filed 2023-02-23 | $367.00K derived: sum of 3 quarters · filed 2023-02-23 | $595.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $249.00K derived: sum of 2 quarters · filed 2023-02-23 | $477.00K derived: sum of 3 quarters · filed 2023-02-23 | $826.00K 10-K · filed 2023-02-23 |
| 2020-09-30 | $125.00K 10-Q · filed 2021-11-10 | $353.00K derived: sum of 2 quarters · filed 2021-11-10 | $702.00K 10-Q · filed 2021-11-10 | $1.00M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $228.00K 10-Q · filed 2021-08-06 | $577.00K 10-Q · filed 2021-08-06 | $877.00K derived: sum of 3 quarters · filed 2022-02-24 | $1.32M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $349.00K 10-Q · filed 2021-05-06 | $649.00K derived: sum of 2 quarters · filed 2022-02-24 | $1.09M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $745.00K derived: sum of 2 quarters · filed 2022-02-24 | $1.00M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $445.00K 10-Q · filed 2020-11-05 | $705.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |